Evidence map›Paper›PMID 37674801›Full record

ArticleTurkish journal of physical medicine and rehabilitation2023

A case of pseudogout attack after zoledronic acid treatment in primary hyperparathyroidism.

Meriç Coşkun, Emre Demir, Abdurrahman Tufan, Afruz Babayeva, Mehmet Muhittin Yalçın, Alev Altınova, Müjde Aktürk, İlhan Yetkin

Open access · diamondAbstract readCase Reports
In one paragraph

Article in Turkish journal of physical medicine and rehabilitation, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Meriç CoşkunDepartment of Internal Medicine, Division of Endocrinology and Metabolism, Gazi University Faculty of Medicine, Ankara, Türkiye.ORCID 0000-0003-4855-6078
Emre DemirDepartment of Internal Medicine, Gazi University Faculty of Medicine, Ankara, Türkiye.ORCID 0000-0002-2501-0868
Abdurrahman TufanDepartment of Internal Medicine, Division of Rheumatology, Gazi University Faculty of Medicine, Ankara, Türkiye.ORCID 0000-0001-6244-9362
Afruz BabayevaDepartment of Internal Medicine, Division of Endocrinology and Metabolism, Gazi University Faculty of Medicine, Ankara, Türkiye.ORCID 0000-0002-3482-541X
Mehmet Muhittin YalçınDepartment of Internal Medicine, Division of Endocrinology and Metabolism, Gazi University Faculty of Medicine, Ankara, Türkiye.ORCID 0000-0002-1041-6881
Alev AltınovaDepartment of Internal Medicine, Division of Endocrinology and Metabolism, Gazi University Faculty of Medicine, Ankara, Türkiye.ORCID 0000-0002-6707-7761
Müjde AktürkDepartment of Internal Medicine, Division of Endocrinology and Metabolism, Gazi University Faculty of Medicine, Ankara, Türkiye.ORCID 0000-0003-0457-6560
İlhan YetkinDepartment of Internal Medicine, Division of Endocrinology and Metabolism, Gazi University Faculty of Medicine, Ankara, Türkiye.ORCID 0000-0001-8905-3771
Gazi University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pseudogout (PG) is an inflammatory arthropathy that develops due to the accumulation of calcium pyrophosphate dihydrate crystals in synovial structures. Herein, we present a 59-year-old male patient with PG developed as a result of zoledronic acid (ZA) infusion, which was administered due to primary hyperparathyroidism. The patient with parathyroid adenoma was given ZA since the calcium level did not decrease despite intravenous saline and loop diuretic. One day after ZA administration, the patient had severe pain, fever, and swelling in joints. The radiograph showed chondrocalcinosis. Calcium pyrophosphate deposition were observed in the arthrocentesis fluid under polarized light. The patient's symptoms regressed after anakinra and colchicine treatment. To the best of our knowledge, this is the first case report of a PG attack after ZA treatment for primary hyperparathyroidism. Additionally, there have been few cases of PG after bisphosphonate treatment for osteoporosis in the literature, signifying that more care should be taken when administering bisphosphonate therapy in patients with risk factors.

Indexed as

Hypercalcemiahyperparathyroidismpseudogoutzoledronic acid.

Identifiers

PMID37674801
PMCPMC10478547
OpenAlexW4385650958

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.